E3 PreliminaryPreliminaryPEM unclearReview-NarrativePeer-reviewedMachine draft
Towards a Better Understanding of the Complexities of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID.
Tate, Warren P, Walker, Max O M, Peppercorn, Katie et al. · International journal of molecular sciences · 2023 · DOI
Quick Summary
ME/CFS is a complex illness that typically starts after a viral infection, though other stressful events can also trigger it. This review explains that different patients experience different combinations of symptoms and respond differently to treatments—what helps one person may not help another. The authors discuss how the immune system may shift from a temporary response to a lasting problem, and how the brain's immune system may cause the neurological symptoms people experience.
Why It Matters
This review is significant because it addresses a fundamental challenge in ME/CFS patient care: the lack of reliable biomarkers and the individual variation in treatment response. By framing ME/CFS as a heterogeneous condition with potentially distinct biological subtypes, it provides a rationale for developing personalized treatment strategies. The connection to Long COVID research opens new funding and research opportunities that may accelerate discovery of therapeutics beneficial to both conditions.
Observed Findings
- Individuals with the same ME/CFS disease profile exhibit unique molecular changes and distinct physiological responses to stress, exercise, and vaccination.
- A common core set of neurological symptoms forms the modern clinical case definition, though symptom combinations vary significantly among patients.
- The shift from transient to chronic immune/inflammatory response appears to involve activation of the brain's specific immune system, resulting in neuroinflammation.
- Identical treatments (drugs, nutraceuticals, or behavioral therapies) produce beneficial, neutral, or detrimental effects depending on individual patient characteristics.
- Long COVID following SARS-CoV-2 infection presents a ME/CFS-like post-viral condition with renewed research interest and investment.
Inferred Conclusions
- ME/CFS likely represents multiple biological subtypes rather than a single disease entity, necessitating phenotype-based classification to guide therapeutic selection.
- The heterogeneity in molecular and physiological responses suggests that precision medicine approaches will be required to match treatments to individual patient biology.
- Brain immune system activation and resulting neuroinflammation appear to be central mechanisms in ME/CFS symptom manifestation.
- Long COVID research provides an unprecedented opportunity to identify therapeutic targets applicable to both post-viral syndromes.
What This Study Does Not Prove
This review does not provide new experimental data or prove specific cause-and-effect relationships in ME/CFS pathogenesis. It cannot establish which susceptibility factors are necessary versus sufficient for disease development, nor does it demonstrate which treatment approaches are definitively effective for particular patient subgroups. The absence of an accessible molecular diagnostic test remains an unresolved limitation that the review acknowledges but does not overcome.
Tags
Symptom:Post-Exertional MalaiseCognitive DysfunctionFatigue
Biomarker:CytokinesGene ExpressionBlood Biomarker
Phenotype:Infection-TriggeredLong COVID Overlap
Method Flag:Exploratory Only
Metadata
- DOI
- 10.3390/ijms24065124
- PMID
- 36982194
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 10 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →